Sangamo price target raised to $27 from $22 at Wedbush Wedbush raised its price target for Sangamo BioSciences to $27 saying the phase 1 results published in the New England Journal of Medicine suggest that the company's ZFN approach to treating HIV has broad acceptance in the medical and scientific communities. The firm reiterats an Outperform rating on the stock.
News For SGMO From The Last 14 Days
Check below for free stories on SGMO the last two weeks.
Sangamo plans to submit IND application for hemophilia B in 2Q15 Sangamo BioSciences (SGMO) plans to submit an Investigational New Drug application for the treatment of hemophilia B in Q2 2015. This program, partnered with Shire (SHPG), is the first therapeutic application of Sangamo's zinc finger nuclease-mediated In Vivo Protein Replacement Platform. Sangamo is developing the IVPRP as a generally applicable strategy to provide a one-time, permanent genetic cure for monogenic diseases that are currently managed by protein replacement therapy, which involves costly repeat infusions over the lifetime of the patient.